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Abstract 24 
Background: β-lactam hypersensitivity has been classified according to the phenotype and 25 
function of drug-specific T-cells; however, new T-cell subsets have not been considered. 26 
Objective: The objective of this study was use piperacillin as a model of β-lactam 27 
hypersensitivity to study the nature of the drug-specific T-cell response induced in the blood 28 
and skin of hypersensitive patients and healthy volunteers.  29 
Methods: Drug-specific T-cells were cloned from blood and inflamed skin and cellular 30 
phenotype and function was explored. Naïve T cells from healthy volunteers were primed to 31 
piperacillin, cloned and subjected to the similar analyses. 32 
Results: PBMC and T-cell clones (n=570, 84% CD4+) from blood of piperacillin 33 
hypersensitive patients proliferated and secreted Th1/2 cytokines alongside IL-22 following 34 
drug stimulation. IL-17A secretion was not detected. Drug-specific clones from inflamed skin 35 
(n=96, 83% CD4+) secreted a similar profile of cytokines, but displayed greater cytolytic 36 
activity, secreting perforin, granzyme B and Fas L when activated. Blood- and skin-derived 37 
clones expressed high levels of skin-homing chemokine receptors and migrated in the 38 
presence of the ligands CCL17 and CCL27. Piperacillin-primed naïve T-cells from healthy 39 
volunteers also secreted IFN-γ, IL-13, IL-22 and cytolytic molecules. Aryl hydrocarbon 40 
(ArH) receptor blockade prevented differentiation of the naïve T-cells into antigen-specific 41 
Il-22 secreting cells.  42 
Conclusion: Together our results reveal that circulating and skin resident antigen-specific IL-43 
22 secreting T-cells are detectable in patients with β-lactam hypersensitivity. Furthermore, 44 
differentiation of naïve T-cells into antigen-specific Th22 cells is dependent on ArH receptor 45 
signalling. 46 
 47 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Sullivan et al 3 
 
 
 
Key messages: (1) β-lactam-specific, IL-22 secreting CD4+ and CD8+ T-cells reside in 48 
blood and inflamed skin of hypersensitive patients: (2) β-lactam primed naïve T-cells from 49 
healthy volunteers secrete the same cytokines and cytolytic molecules: (3) Differentiation of 50 
naïve T-cells into antigen-specific Th22 cells is dependent on ArH receptor signalling. 51 
 52 
Capsule summary: New T-cell subsets have not been considered in the context of drug 53 
hypersensitivity. Herein, we show that antigen-specific circulating and skin resident CD4+ 54 
and CD8+ T-cells secrete IL-22 and cytolytic molecules following drug treatment.   55 
 56 
Keywords: Human, T-cells, drug hypersensitivity.  57 
 58 
Abbreviations: Stimulation index, SI; peripheral blood mononuclear cells, PBMC.  59 
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Introduction 60 
To understand the cellular pathophysiology of different forms of hypersensitivity reaction, 61 
antigen-specific T-cells have been cloned from the peripheral blood of hypersensitive patients 62 
and characterized in terms of cellular phenotype and function.1-4 Data deriving from these 63 
studies indicated that delayed-type hypersensitivity reactions could be categorized according 64 
to the phenotype of drug-specific T-cells, the cytokines they secrete and pathways of 65 
immune-mediated killing of target cells.5 Essentially, reactions were divided into 4 subsets. 66 
In the last decade, our knowledge of the mechanistic basis of drug hypersensitivity has 67 
increased exponentially. For example, we now know that (1) herpes virus reactivation is 68 
implicated in certain reactions,6,7 (2) HLA allele expression is an important determinant for 69 
susceptibility8,9 and (3) specific forms of drug-induced kidney and liver injury should fall 70 
under the definition of drug hypersensitivity.10-13 Despite this, our knowledge of the T-cells 71 
that instigate and/or regulate drug hypersensitivity reactions has not progressed significantly 72 
in the last decade.  73 
 74 
The cytokine milieu that naïve T-cells are exposed to at the time of antigen exposure and 75 
during differentiation is known to determine the nature of the antigen-specific response and 76 
the types of secretory molecules that can affect tissue cells. In recent years, memory CD4+ 77 
and CD8+ T-cells have been shown to secrete distinct cytokine signatures: Th1 (IFN-γ), Th2 78 
(IL-4, IL-5, IL-13), Th17 (IL-17, IL-22) and Th22 (IL-22). However, the picture is 79 
complicated somewhat since the cytokines IL-17 and IL-22 can also be secreted by Th1/Th2 80 
T-cells.14,15 IL-22 is thought to be of particular importance in allergic skin disease since 81 
receptors that the cytokine binds to are expressed on epithelial cells including keratinocytes.16 82 
Moreover, Th17 and Th22 secreting T-cell subsets tend to express chemokine receptors that 83 
promote skin migration (e.g., CCR4, CCR10).17 Since human skin is protected by discrete 84 
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populations of resident and recirculating T-cells18 we have isolated and cloned drug-specific 85 
T-cells from blood and skin of hypersensitive patients and characterized their cellular 86 
phenotype and function following antigen recall, to determine whether IL-17 and/or IL-22 87 
participate in drug hypersensitivity reactions. Previous studies with human T-cells isolated 88 
from the memory T-cell pool have shown a mixed cytokine pattern, with small shifts in 89 
balance toward a dominant cytokine. Thus, our patient studies were conducted in parallel to 90 
T-cell priming experiments utilizing PBMC from healthy volunteers and a recently described 91 
dendritic cell T-cell co-culture system.19 This assay is simple to manipulate, which allowed 92 
us to assess the influence of aryl hydrocarbon (ArH) receptor signalling on the nature of the 93 
primary drug-specific response.  94 
 95 
 96 
Piperacillin hypersensitivity was selected as the study model for several reasons. Firstly, 97 
piperacillin is a β-lactam antibiotic and antibiotic hypersensitivity is the most common form 98 
of drug-induced allergic disease. Secondly, piperacillin forms drug antigens directly in 99 
patients and in vitro through the selective covalent modification of lysine residues on proteins 100 
such as human serum albumin.20 Thirdly, piperacillin is a commonly prescribed drug and the 101 
frequency of hypersensitivity has been estimated to be as high as 35% in patients with cystic 102 
fibrosis.21 Finally, PBMC and blood-derived T-cell clones have been shown to be activated in 103 
vitro in the presence of piperacillin and piperacillin albumin conjugates.22  104 
 105 
 106 
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Methods 108 
Human subjects and cell isolation/separation 109 
Venous blood (20-60ml) was collected from 4 piperacillin hypersensitive patients with cystic 110 
fibrosis and 4 control subjects who had been exposed to at least one course of piperacillin 111 
with no recorded adverse event. PBMC were isolated and used for the lymphocyte 112 
transformation test, generation of EBV-transformed B-cells and T-cell cloning. Punch biopsy 113 
samples (3mm) were obtained from 2 of the hypersensitive patients (patients 1 and 2) 114 
following a positive 24h intradermal skin test. The intravenous preparation of Tazocin 115 
(piperacillin-tazobactam) was used for intradermal testing at a concentration of 2mg/ml. A 116 
volume of 0.02ml was injected using a 0.5mm X 16mm insulin needle, this created an 117 
injection wheal of around 3mm. Between 24 to 48 hours an infiltrated erythema over 5mm 118 
was seen and a punch biopsy performed. Skin was broken up using a scalpel and cultured in 119 
medium containing IL-2 (100IU/ml) for 5 days. T-cells migrating into culture medium were 120 
collected, passed through a 50µm strainer and used for T-cell cloning.  121 
 122 
PBMC were also isolated from 120ml of blood from 4 healthy volunteers to study the 123 
priming of naïve T-cells with piperacillin.  Monocytes and naïve T-cell populations were 124 
separated using magnetic microbeads (Miltenyi Biotech; Bisley, UK). CD14+ cells were 125 
positively selected from total PBMC. For isolation of naïve T-cells, pan negative T-cell 126 
separation was performed using an anti-T-cell antibody cocktail. CD3+ cells were then 127 
subject to positive selection to remove the unwanted CD25+ Treg and memory cells 128 
(CD45RO+). The naïve T-cells prior to priming were consistently greater than 98% pure. The 129 
purity of the CD14+ monocytes varied depending on the level of neutrophil contamination in 130 
the PBMC preparation but was generally greater than 80%.  Monocyte-derived dendritic cells 131 
were 100% positive for CD40, CD58, CD86 and Class I and Class II expression. 132 
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 133 
Approval for the study was obtained from the Liverpool and Leeds local research ethics 134 
committees and informed written consent was received from participants prior to inclusion in 135 
the study. 136 
 137 
Medium for T-cell culture and cloning 138 
Culture medium consisted of RPMI-1640 supplemented with pooled heat-inactivated human 139 
AB serum (10%, v/v), HEPES (25mM), L-glutamine (2mM), transferrin (25g/mL), 140 
streptomycin (100g/mL), and penicillin (100U/mL). IL-2 (100IU/ml) was added to establish 141 
drug-specific T-cell lines and clones.   142 
 143 
Lymphocyte transformation test and PBMC ELIspot 144 
PBMC (1.5x105 cell/well) from hypersensitive patients and tolerant controls were incubated 145 
with piperacillin (0.5-4mM) or tetanus toxoid (5g/mL, as a positive control) in culture 146 
medium for 5 days. [3H]thymidine was added for the final 16h of the experiment. IFN-γ, IL-147 
13, IL-17 and IL-22 secreting PBMC were visualized using ELIspot (MabTech, Nacka 148 
Strand, Sweden) by culturing PBMC (5x105 cell/well) in culture medium with piperacillin 149 
(0.5-2mM) for 48h.  150 
 151 
Priming of naïve T-cells from healthy volunteers  152 
CD14+ monocytes were cultured for 8 days in culture medium containing GM-CSF and IL-4 153 
(800U/ml) to generate dendritic cells.  On day 7, TNF-α (25ng/ml) and LPS (1µg/ml) were 154 
added to induce maturation. Mature dendritic cells (0.8x105/well; total volume 2ml) were 155 
cultured with CD3+CD25-CD45RO- naive T cells (2.5x106/well) and piperacillin (2mM) or 156 
nitroso sulfamethoxazole (50µM; as a positive control) in a 24-well plate for 7 days. The 157 
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experiment was repeated following inclusion of: (1) TGFβ (5ng/ml), IL1-β (10ng/ml) and IL-158 
23 (20ng/ml) to polarize the induction protocol towards a Th17 phenotype or TNFα 159 
(50ng/ml) and IL-6 (20ng/ml) to polarize towards a Th22 phenotype and (2) ArH receptor 160 
agonist (VAF347, 50nM) or ArH receptor antagonist (CH-223191, 100nM; Millipore, 161 
Watford, UK). 162 
 163 
Primed T-cells (1x105/well) were re-stimulated using dendritic cells (4x103/well) and either 164 
piperacillin (0.5mM-2mM) or nitroso sulfamethoxazole (12.5-50µM). After 48h, proliferative 165 
responses and cytokine release were measured using [3H]thymidine and IFN-γ, IL-13, IL-17 166 
or IL-22 ELIspot, respectively. 167 
 168 
Generation of EBV-transformed B-cells 169 
Epstein-Barr virus transformed B-cell lines were generated from PBMC and used as antigen 170 
presenting cells in experiments with T-cell clones.  171 
 172 
Generation of drug-specific T-cell clones   173 
PBMC (1-5x106/ml) from hypersensitive patients were incubated with piperacillin (2mM) in 174 
IL-2 containing medium to establish drug-responsive T-cell lines. After 14 days, T-cells were 175 
serially diluted (0.3-3 cells/well), and subjected to PHA-driven expansion (5µg/ml). 176 
Irradiated allogeneic PBMC (5x104/well) were added as feeder cells. After 28-42 days, clones 177 
expanded to approximately 5x105 cells were tested for piperacillin specificity by culturing the 178 
drug (2mM; 200µl total volume) with clones (5x104 cells/well) and irradiated EBV-179 
transformed B-cells (1x104 cells/well) for 48h in triplicate cultures per experimental 180 
condition. Proliferation was measured by the addition of [3H]thymidine followed by 181 
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scintillation counting. Clones with a stimulation index (mean cpm drug-treated wells / mean 182 
cpm in control wells) of greater than 2 were expanded and analysed further.  183 
 184 
T-cells from inflamed patient skin and healthy volunteer PBMC after priming were cloned 185 
using the same procedure.  186 
 187 
Dose-dependent proliferative responses and the profile of secreted cytokines (IFN-γ, IL-13, 188 
granzyme B, Fas L, perforin, IL-17 and IL22) were measured using [3H]thymidine and 189 
ELIspot, respectively. The ELIspot reader accurately counts spots up to approximately 400; 190 
thus, giving an upper limit to the assay.  Not all T-cells in a clonal population are capable of 191 
responding. There are several reasons for this: 1, TCR stimulation and co-stimulation must be 192 
optimal; 2, the level/form of antigen presented by individual antigen presenting cells may not 193 
be optimal; 3, some of the T cells may not interact with antigen presenting cells and 4, the 194 
ability of the T-cell to respond depends on the cell being in resting stage or G0 of the cell 195 
cycle. Thus, preliminary experiments were conducted to optimize cell numbers. Eventually, 196 
T-cell clones (5x104) were cultured with irradiated antigen presenting cells (1x104) and 197 
piperacillin (2mM; 200µl) for 48 h to analyse cytokine secretion. Representative ELIspot 198 
images showing IL-22 secretion from piperacillin-treated clones are displayed in Figure E1 199 
(in the journals online repository). T-cell clones cultured in medium alone have low spot 200 
counts ie below the 100 cut-off value which represents “the negative”. The 100 cut-off value 201 
was calculated by taking the mean + 2 SD of control wells of 2 key cytokines (IFN-γ and 202 
IL22) and granzyme B (70, 96 and 88 sfu, respectively). 95% of control values are expected 203 
to lie within this band around the mean. Flow cytometry and ELISA were used to measure 204 
expression of the key cytokines IFN-γ and IL-22. Cell phenotyping was performed by flow 205 
cytometry. TCR Vβ expression was measured using the IOTest® Beta Mark, TCR Vβ 206 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Sullivan et al 10 
 
 
 
Repertoire Kit (Beckman Coulter). Antibodies used for flow cytometry staining purchased 207 
from BD Biosciences (Oxford, UK) were CD4-APC (clone RPA T4), CD8-PE (clone 208 
HIT8a), CCR4-PE (clone 1G1), CLA-FITC (clone HECA-452); from eBIoscience Ltd 209 
(Hatfield, UK) were IFNg-Alexa Fluor 488 (clone 4S.B3), IL-13-PE (clone 85BRD), IL-22-210 
eFluor660 (clone 22URTI), isotype controls mouse IgG1-Alexa Fluor 488, mouse IgG1-PE, 211 
mouse IgG1-eFluor660 and from R&D Systems (Abingdon, UK) were CCR1-Alex Fluor 488 212 
(clone 53504), CCR2-PE (clone 48607), CCR3-FITC (clone 61828), CCR5-FITC (clone 213 
CTC5), CCR6-APC (Clone 53103), CCR8 –PE (clone 191704),  CCR9-APC (clone 248621), 214 
CCR10-PE (clone 314305), CXCR1-FITC (clone 42705), CXCR3-APC (clone 49801), 215 
CXCR6-PE (clone 56811) and E cadherin-Alexa Fluor 488 (clone 180224). Approximately 216 
1x105 T cell clones were stained for surface markers using directly conjugated antibodies. 217 
The cells were incubated on ice for 20 min and then washed with 1ml 10% FCS in HBSS. 218 
Chemokine receptor expression is presented as median fluorescence intensity of the whole 219 
population of each clone and percentage of cells expressing each receptor.   For intracellular 220 
cytokine analysis clones (1x105) were cultured with irradiated antigen presenting cells 221 
(0.2x105) and piperacillin (2mM) for 24 h. GolgiStop was added for the last 4 hours of 222 
culture. Cells were then fixed and permeabilized using the BD Cytofix/Cytoperm Kit (BD 223 
Biosciences, Oxford, UK) and incubated with anti-cytokine antibodies for 30 min on ice and 224 
washed once. All cells were acquired using a FACSCanto II (BD Biosciences, Oxford, UK) 225 
and data analyzed by Cyflogic. A minimum of 50,000 lymphocytes were acquired using 226 
FSC/SSC characteristics. ELISA was conducted using human IFN-γ, IL-13 and IL-22 Ready-227 
SET-Go kits (eBioscience, Ltd) according to the manufacturer’s instructions.  228 
 229 
Chemotaxis assays were performed using 5µm-pore containing 24-well transwell plates. T-230 
cells (1x105) were added to the upper chambers and placed in medium containing different 231 
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chemotactic molecules (CCL2, CCL4, CCL17, CCL25, CCL27, CXCL9, CXCL16; 100nM).  232 
Time-dependent chemotactic migration was recorded using a haemocytometer between 1-233 
24h. 234 
 235 
Statistics  236 
All statistical analysis (One-way ANOVA unless stated otherwise) was performed using 237 
SigmaPlot 12 software (*P<0.05).  238 
 239 
  240 
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Results 241 
PBMC from piperacillin hypersensitive patients proliferate and secrete IFN-γ, IL-13 242 
and IL-22 following drug stimulation 243 
PBMC from 4 hypersensitive patients were stimulated to proliferate with piperacillin in a 244 
dose-dependent manner (0.25-4mM). At the optimal concentration of 2mM piperacillin, the 245 
SI ranged from 20-62. Proliferative responses were also detected with the positive control 246 
tetanus toxoid (Figure 1A).  In contrast, PBMC from drug tolerant controls proliferated in the 247 
presence of tetanus toxoid, but not piperacillin (SI less than 1.5; results not shown).   248 
 249 
Cytokine secretion from piperacillin-stimulated hypersensitive patient PBMC were analysed 250 
using ELIspot. Significant levels (P<0.05) of IFN-γ, IL-13 and IL-22 were secreted from 251 
piperacillin (and PHA) treated cultures, when compared with cultures containing medium 252 
alone (Figure 1B).  Although PHA treatment of hypersensitive patient PBMC was associated 253 
with the secretion of IL-17, piperacillin-specific IL-17 secretion was not detected.  254 
 255 
Piperacillin-specific CD4+ and CD8+ clones from PBMC and inflamed skin of 256 
hypersensitive patients secrete IL-22 257 
A total of 570 clones responsive to piperacillin were generated from PBMC of the four 258 
hypersensitive patients (39.5% response rate [clones with an SI of 2 or more]; Figure 1C and 259 
D).  The piperacillin-responsive clones were predominantly CD4+; however, drug-specific 260 
CD8+ clones were isolated from each patient. Proliferative responses were concentration-261 
dependent with optimal responses detected using a concentration of 2mM piperacillin (results 262 
not shown). Following expansion of the clones, 43 CD4+ and CD8+ well-growing clones, 263 
randomly selected from the 4 patients, were used for analysis of cytokine secretion. Clones 264 
expressed single, but varied VCR Vβ chains.  265 
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 266 
Activation of the clones with piperacillin resulted in the secretion of IFN-γ, IL-13 and IL-22; 267 
however, IL-17 was not detected (Figure 1E). Clones were also isolated from the skin of 268 
hypersensitive patients 1 and 2 following a positive intradermal test. Ninety six piperacillin-269 
responsive clones were generated from a total of 690 tested (response rate, 13.9%) (Figure 270 
2A and B). Analogous to the experiments with PBMC, the majority of drug-specific clones 271 
were CD4+. Twenty four well-growing clones were selected for analysis of cytokine 272 
secretion. Drug-treatment was associated with the release of IFN-γ, IL-13 and IL-22, but not 273 
IL-17 (Figure 2C).   274 
 275 
Figure 3A shows the levels of IFN-γ and IL-13 secreted from individual clones. Clones 276 
secreting Th1 (IFN-γhigh, IL-13low), Th2 (IFN-γlow, IL-13high), and Th1/2 (IFN-γhigh, IL-13high) 277 
cytokines following drug stimulation were detectable with blood- and skin-derived clones. 278 
However, with the skin-derived clones the response was much more polarized and clones 279 
secreting low-moderate levels of cytokines were rarely seen.  280 
 281 
Figure 3B shows the mean levels of IL-22 secretion from individual clones. Figure 3C shows 282 
the level of IFN-γ and IL-13 secreted from the IL-22high clones (i.e., clones forming at least 283 
100 sfu above control values after piperacillin treatment). These data illustrate that (1) CD4+ 284 
and CD8+ clones secrete IL-22, (2) most blood-derived IL-22high clones secrete IFN-γ and IL-285 
13, (3) most skin-derived IL-22high clones secrete IFN-γ alone and (4) the response of the 286 
skin-derived clones is highly polarized. Flow cytometry was used to measure intracellular 287 
expression of IFN-γ and IL-22 with a panel of IFN-γhigh, IL-22high and IFN-γhigh, IL-22low 288 
clones. For the IL-22high clones, all cells in the culture secreted IFN-γ and IL-22, whereas the 289 
IL-22low clones only expressed IFN-γ (Figure E2). Protein secretion was confirmed by 290 
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measuring IFN-γ and IL-22 secretion in culture supernatants using specific ELISA. 291 
Piperacillin-treatment of IL-22high resulted in the secretion of IFN-γ and IL-22 into culture 292 
supernatant. In contrast, with the IL-22low clones only IFN-γ was detected (Figure E3).  293 
 294 
Skin-derived piperacillin-specific clones secrete perforin, granzyme B and Fas L 295 
Clones deriving from blood (n=24) and skin (n=24) secreted high levels of granzyme B 296 
(Figure 3D). However, significantly higher levels of perforin and Fas L were detected from 297 
the piperacillin-treated skin-derived clones. Interestingly, piperacillin-specific CD4+ clones 298 
secreted the highest levels of FasL and perforin (Figure 3E).   299 
 300 
Chemokine receptor expression on piperacillin-specific T-cell clones 301 
Expression of 12 chemokine receptors, CLA, CD69 and E-CAD were compared on 302 
piperacillin-specific blood- and skin-derived clones (n=24-36 per group). Piperacillin-specific 303 
blood and skin-derived clones expressed high levels of CD69 (Figure E4). Skin-derived 304 
clones that were not activated with piperacillin were used as an additional comparator. 305 
Piperacillin-specific skin and blood-derived clones were found to express multiple chemokine 306 
receptors including CCR4, 5, 8, 9 and 10 and CXCR1, 3 and 6 when flow cytometry data 307 
were analysed as MFI (Figure 4) or % positive cells (Figure E5) Skin-derived piperacillin-308 
specific clones expressed significantly higher levels of CCR1 and CLA, compared with non-309 
specific clones. Blood-derived piperacillin-specific clones expressed higher levels of CCR9 310 
when compared with the skin-derived piperacillin-specific and non-specific clones. In 311 
contrast, CCR2, CXCR1, and CLA were expressed at higher levels on the piperacillin-312 
specific skin-derived clones, when the two populations of piperacillin-specific clones were 313 
compared.  (Figure 4; Figure E5). Representative dot plot images showing the panel of 314 
receptors expressed and analysed in terms of MFI and % positive cells are shown in Figure 315 
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E6. Finally, it was possible to use quadrant analysis too obtain data from double-positive 316 
populations for chemokine receptors CXCR1 and CXCR 3, and CCR8 and CCR10. The 317 
representative traces shown in Figure E7 illustrate that the majority of piperacillin-specific T-318 
cells express both chemokine receptors. 319 
 320 
No significant correlation between chemokine receptor expression and IL-22 secretion by 321 
piperacillin-stimulated clones was observed (Figure E8). However, skin- and blood-derived 322 
IL-22 secreting clones had a tendency to express CCR4 and lower levels of CCR4, 323 
respectively.    324 
 325 
All clones were found to migrate across transwell membranes, in a time-dependent manner, 326 
in the presence of the CCR4 and CCR10 ligands, CCL17 and CCL27, respectively (Figure 5). 327 
Furthermore, the blood-derived clones, which expressed significantly higher levels of CCR9, 328 
migrated in the presence of CCL25, a ligand for CCR9. Interestingly, all clones migrated to a 329 
similar extent, which suggests that threshold levels of chemokine receptor expression 330 
determine whether a clone will migrate in the presence of the relevant ligand.  331 
 332 
Priming of naïve T-cells against piperacillin generates antigen-specific Th22 secreting 333 
clones 334 
Naïve T-cells from four volunteers were cultured in the presence of autologous monocyte-335 
derived dendritic cells (CD11ahigh CD11chigh CD14neg CD80high CD86high MHC class IIhigh) 336 
and piperacillin for 8 days. Primed T-cells were then cultured with a second batch of 337 
dendritic cells and the drug and antigen specificity was assessed. Upon restimulation, 338 
piperacillin concentration-dependent proliferative responses were clearly detectable (Figure 339 
6A). The strength of the induced response was similar to that seen with cells from 340 
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hypersensitive patients. Moreover, piperacillin-primed cells were not activated with the 341 
control antigen nitroso sulfamethoxaozle. Similarly, nitroso sulfamethoxaozle-primed T-cells 342 
were not activated with piperacillin (results not shown).  343 
  344 
Piperacillin stimulation of the primed cells resulted in the secretion of IFN-γ, IL-13 and IL-345 
22, but IL-17 was not detected (Figure 6B). The priming experiment was repeated in the 346 
presence of cytokine cocktails known to polarize T-cells towards Th17 and Th22 subsets. No 347 
qualitative difference in the profile of cytokines secreted from piperacillin-specific T-cells 348 
was observed. In particular, IL-17 was not detected (results not shown). 349 
 350 
Sixty-four piperacillin-responsive clones were generated from the 4 volunteers, out of a total 351 
of 526 tested (response rate: 12.2%) (Figure 6C and 6D). Piperacillin-specific CD4+ and 352 
CD8+ clones were detected; however, in contrast to clones from hypersensitive patients, most 353 
expressed CD8+. Thirty seven well-growing clones were tested and found to secrete IFN-γ, 354 
IL-13 and IL-22, but not IL-17, following treatment with piperacillin (Figure 6E).  355 
 356 
Analysis of the profile of cytokines secreted from individual clones revealed that most CD4+ 357 
and CD8+ clones secreted high levels of IFN-γ (Figure 7A). The few clones that secreted 358 
high levels of IL-22 were all CD8+ and did not secrete other cytokines (i.e., IFN-γ, IL-13 and 359 
IL-17) (Figure 7B-D).   360 
 361 
Signalling through the aryl hydrocarbon receptor is critical for the generation of 362 
piperacillin-specific IL-22 secreting T-cells 363 
To investigate whether the generation of piperacillin-specific IL-22 secreting T-cells is 364 
regulated through the ArH receptor, naïve T-cell priming was studied in the presence of an 365 
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ArH receptor agonist or antagonist. Restimulation of T-cells primed in the presence of the 366 
ArH receptor agonist resulted in the secretion of IFN-γ, IL-13, IL-22, perforin, granzyme B 367 
and Fas L. T-cells primed in the presence of the ArH receptor antagonist secreted IFN-γ, IL-368 
13, perforin, granzyme B and Fas L following restimulation with piperacillin; however, IL-22 369 
secretion was no longer detected (Figure 8A and 8B).      370 
  371 
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Discussion 372 
To develop an effective classification of drug hypersensitivity, one must identify factors that 373 
contribute to and discriminate between the spectrum of diseases that fall under that definition. 374 
Classifying by drug is not effective since most that are associated with a high frequency of 375 
reactions cause a range of adverse events. Similarly, classifying by HLA risk alleles doesn’t 376 
work as the same MHC molecule might predispose individuals to different forms of 377 
hypersensitivity reaction (e.g., HLA-B*57:01; abacavir hypersensitivity & flucloxacillin-378 
induced liver injury).23 The existing classification of delayed-type drug hypersensitivity 379 
categorizes reactions based on the phenotype and function of drug-specific T-cells;5 however, 380 
new T-cell subsets have never been considered. With this in mind, the current study focussed 381 
on IL-17 and IL-22 as these cytokines are now believed to be important mediators of allergic 382 
reactions in the skin,16,24 but have not been studied extensively in the context of drug 383 
hypersensitivity. Piperacillin was selected as the study drug as β-lactam hypersensitivity is 384 
the most common form of allergic drug reaction. To obtain a detailed assessment of the drug-385 
specific response, T-cells were cloned from blood and inflamed skin of the same 386 
hypersensitive patients. Furthermore, naïve T-cells from healthy volunteers were primed 387 
against piperacillin to study factors that govern the development of a drug-specific T-cell 388 
response.  389 
 390 
The lymphocyte transformation test and PBMC ELIspot are used routinely for 391 
hypersensitivity diagnosis and to characterize the culprit drug.25-26 In agreement with our 392 
previous studies,20,22 PBMC from hypersensitive patients, but not tolerant controls, were 393 
stimulated in the presence of piperacillin to proliferate and secrete the Th1/2 cytokines IFN-γ 394 
and IL-13. Moreover, PBMC from hypersensitive patients secreted high levels of IL-22, 395 
while IL-17 was not detected. IL-17 secretion was, however, detected from mitogen-396 
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stimulated PBMC. Thus, its absence from drug-treated PBMC suggests that piperacillin-397 
specific IL-17 secreting T-cells do not circulate in the peripheral blood of hypersensitive 398 
patients. The failure to detect piperacillin-specific responses from the tolerant patient group 399 
(and drug-naïve donors) may relate to differences in the abundance of precursor cells at the 400 
time of drug exposure. Future studies should attempt to quantify the difference using 401 
established culture methods.27.   402 
 403 
To determine the source of the secreted cytokines, over 500 piperacillin-specific T-cell clones 404 
were generated; drug treatment was associated with the secretion of Th1 (IFN-γhigh), Th2 (IL-405 
13high) or a mixed phenotype panel of cytokines (IFN-γhigh, IL-13high). Given that human skin 406 
is protected by skin-resident and recirculating T-cells with distinct functional activity18 it was 407 
important to compare the piperacillin-specific blood-derived T-cells with T-cells isolated 408 
from inflamed skin. These comparative studies gained further credence when Gaide et al28 409 
demonstrated, using a mouse model of contact dermatitis, that skin resident and central 410 
memory T-cells derive from a common origin. The authors reported that skin resident cells 411 
responded rapidly following antigen challenge, whereas central memory cells were recruited 412 
to the tissue more slowly to mediate a delayed response. Similar to the blood-derived clones, 413 
approximately 85% of piperacillin-responsive clones isolated from inflamed skin were CD4+ 414 
and drug treatment resulted in the secretion of the same cytokines, namely IFN-γ, IL-13 and 415 
IL-22, but not IL-17. Most of the skin-derived clones secreting IL-22 were of the Th1 416 
phenotype. IL-22 binds to receptors expressed on cells such as keratinocytes to mediate 417 
innate responses in skin. Although IL-22 has been described as a protective cytokine, it also 418 
promotes pathogenic responses when secreted, as we have found, in the presence of other 419 
cytokines.29 For example, CD4+ and CD8+ T-cells that secrete IFN-γ and IL-22 are 420 
implicated in the pathogenesis of chronic skin conditions such as psoriasis.30 Collectively, our 421 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Sullivan et al 20 
 
 
 
data shows that IL-22 signalling participates in maculopapular drug eruptions; however, 422 
additional studies are required to delineate whether IL-22 is acting to promote disease 423 
progression or alternatively regulate the severity of tissue injury. 424 
 425 
Fas L, perforin and granzyme B are T-cell secretory molecules that act in unison to induce 426 
apoptosis in tissue cells. Early studies by Posadas et al31 reported upregulated levels of 427 
perforin and granzyme B in PBMC isolated from patients with acute mild and severe forms 428 
of drug-induced skin injury. Moreover, a strong correlation was observed between the level 429 
of cytolytic molecules and severity of the disease. In contrast, Fas L was only observed in 430 
patients with Stevens Johnson syndrome and toxic epidermal necrolysis. More recently, 431 
Zawodiniak et al32 utilized a granzyme B ELIspot to detect cytotoxic T-cells in blood of 432 
patients with various forms of drug-induced skin injury. Accordingly, we utilized drug-433 
specific clones isolated from blood and skin of the same hypersensitive patients to measure 434 
and compare Fas L, perforin and granzyme B secretion. Blood and skin-derived clones 435 
secreted high levels of granzyme B when activated with piperacillin, which to some extent 436 
explains the findings of Zawodiniak et al.32 In contrast, perforin and Fas L secretion was 437 
largely restricted to the skin-derived clones. These data show that (1) drug-specific skin 438 
resident T-cells are the most likely mediators of tissue injury and (2) analysis of blood-439 
derived T-cells alone underestimates the importance of cytolytic molecules in the disease 440 
pathogenesis. 441 
 442 
A subset of T-cells expressing the skin homing chemokine receptors CCR4 and CCR10 have 443 
previously been shown to secrete IL-22 and hence are thought to be important mediators of 444 
skin pathophysiology.33 Furthermore, ligands for CCR4 (CCL17) and CCR10 (CCL27), 445 
which contribute towards the recruitment of IL-22 secreting cells, have been found at high 446 
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levels in the lesional skin of patients with atopic dermatitis.34,35 Thus, the next component of 447 
our study was to characterize expression of chemokine receptors on blood- and skin-derived 448 
piperacillin-specific IL-22 secreting clones and to measure migratory potential of the clones 449 
towards relevant chemokines. Blood and skin-derived CD4+ and CD8+ clones were found to 450 
express multiple chemokine receptors including CCR4, 5, 8, 9 and 10 and CXCR1, 3 and 6. 451 
Interestingly, CLA was expressed in higher levels on the skin-derived clones. Comparison of 452 
chemokine receptor expression and IL-22 secretion revealed that skin-derived IL-22 secreting 453 
clones had a tendency to express higher levels of CCR4 and the opposite was true for blood-454 
derived clones. Most importantly, both skin- and blood-derived clones migrated towards 455 
CCL17 and CCL27 (i.e., ligands for the 2 chemokine receptors). Interestingly, the blood 456 
derived clones expressed high levels of CCR9, a receptor more traditionally associated with 457 
homing towards the gastrointestinal tract,36 and migrated in the presence of the CCR9 ligand, 458 
CCL25, which suggests that drug-specific T-cells in blood have the capacity to migrate to 459 
different locations around the body.  460 
 461 
Cell culture platforms have been developed in recent years to study the priming of naïve T-462 
cells against chemical and drug antigens.19,37,38 In these assays, naïve T-cells from healthy 463 
donors are cultured with autologous dendritic cells and the chemical/drug for 7-14 days. The 464 
newly primed T-cells are then restimulated with a second batch of dendritic cells and a range 465 
of compounds to assess antigen specificity. We utilized these methods to characterize the 466 
panel of cytokines secreted by naïve T-cells (from 4 healthy volunteers) primed against 467 
piperacillin. Following restimulation, the piperacillin-primed cells proliferated vigorously and 468 
secreted IFN-γ, IL-13 and IL-22. Importantly, IL-22 was seen in the absence of polarizing 469 
cytokines such as IL-6 and TNF-α, which promote the differentiation of naive T-cells into IL-470 
22 secreting effectors.33 T-cells cloned from the piperacillin-primed naïve T-cells were 471 
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skewed towards a CD8+ phenotype and drug stimulation resulted in the secretion of high 472 
levels of IFN-γ and low-moderate levels of IL-13 and IL-22. Analysis of individual clones 473 
revealed that the three clones secreting high levels of IL-22 were CD8+. They did not secrete 474 
Th1 or Th2 cytokines. Antigen-specific T-cells with this phenotype are rarely reported in the 475 
literature16,39 and their role in allergic disease needs to be investigated further. The reason 476 
why CD8+ clones were detected in a high frequency from healthy volunteers is not clear, but 477 
possibly relates to (1) differences in drug concentration during priming or (2) a different 478 
mechanism of drug presentation as we have recently reported with the β-lactam 479 
flucloxacillin.11,40  480 
 481 
The transcription factor ArH recptor regulates the differentiation of naïve T-cells into IL-22 482 
secreting cells. Selective ArH receptor antagonists have been shown to perturb the production 483 
of IL-22 secreting cells from naïve precursors, whereas memory T-cells are refractory to ArH 484 
receptor regulation.41,42 In the final component of the project, naïve T-cells were primed 485 
against piperacillin in the presence of an ArH receptor agonist (VAF347) and antagonist 486 
(CH-223191). T-cells primed to piperacillin in the presence of VAF347 secreted IFN-γ, IL-13 487 
and IL-22 alongside cytolytic molecules perforin, granzyme B and Fas L following 488 
restimulation with the drug. In parallel experiments with CH-223191, the differentiation of 489 
naïve T-cells into piperacillin-specific IL-22 secreting cells was blocked, while all other 490 
secretory molecules were detected at essentially the same level. Thus, ArH receptor 491 
signalling is critical for the generation of drug-specific IL-22 secreting T-cells.   492 
 493 
In conclusion, our study shows that circulating and skin-resident CD4+ and CD8+ T-cells 494 
that secrete IL-22, but not IL-17, alongside cytolytic molecules are important mediators of β-495 
lactam hypersensitivity in humans. Differentiation of naïve T-cells into drug-specific IL-22 496 
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secreting cells is dependent on ArH receptor signalling. The reason why β-lactam 497 
hypersensitivity reactions are so common in patients with cystic fibrosis might relate to 498 
clinical practice: drugs are administered at high intravenous concentrations for a long 499 
duration and on a repeated basis. Moreover, enhanced risk might relate to the inflammatory 500 
response in patients with cystic fibrosis. The lungs of a patient with cystic fibrosis exist in a 501 
chronic acute responsive state with high numbers of neutrophils and cytokines such as IL-8, 502 
IL-1β, IL-6, and TNF-α. In fact, the local cytokine environment might polarize the drug-503 
specific T-cell response towards the Th22 profile identified herein. 504 
 505 
  506 
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Figure legends 632 
Figure 1. PBMC and T-cell clones from blood of hypersensitive patients proliferate and 633 
secrete IFN-γ, IL-13 and IL-22 when stimulated with piperacillin. (A) PBMC from 634 
hypersensitive patients were cultured with piperacillin for 5 days at 37oC. [3H]thymidine was 635 
added for the final 16h to measure PBMC proliferation. (B)  PBMC from hypersensitive 636 
patients were cultured with piperacillin for 2 days at 37oC. Cytokine secretion was visualized 637 
by ELIspot. Images from 2 representative patients are shown. (C) Table shows the number of 638 
piperacillin-responsive T-cell clones generated from blood of hypersensitive patients and 639 
their CD phenotype. (D) T-cell clones were cultured with irradiated antigen presenting cells 640 
and piperacillin and proliferative responses were measured. (E) T-cell clones were cultured 641 
with irradiated antigen presenting cells and piperacillin and cytokine secretion was 642 
quantified..  643 
 644 
Figure 2. T-cell clones from inflamed skin of hypersensitive patients proliferate and 645 
secrete IFN-γ, IL-13 and IL-22 when stimulated with piperacillin. (A) Table shows the 646 
number of piperacillin-responsive T-cell clones generated from skin of hypersensitive 647 
patients and their phenotype. (B) T-cell clones were cultured with irradiated antigen 648 
presenting cells and piperacillin and proliferative responses were measured. (C) T-cell clones 649 
were cultured with irradiated antigen presenting cells and piperacillin and cytokine secretion 650 
was quantified.  651 
 652 
Figure 3. Profile of cytokine and cytolytic molecules secreted from piperacillin-specific 653 
T-cell clones derived from blood and inflamed skin of hypersensitive patients. T-cell 654 
clones were cultured with irradiated antigen presenting cells and piperacillin and secretions 655 
were quantified. (A) Comparison of IFN-γ and IL-13 secreted by individual blood- and skin-656 
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derived T-cell clones. Filled circles depict CD8+ clones. (B) Mean ± SD IL-22 secretion from 657 
Th1, Th2 and Th1/2 clones. (C) Comparison of the level of IFN-γ and IL-13 secreted by 658 
individual IL-22hhigh blood- and skin-derived T-cell clones. (D) Cytolytic molecules secreted 659 
by piperacillin-specific clones. (E) Comparison of the level of perforin and Fas L secreted by 660 
individual blood- and skin-derived T-cell clones.  661 
 662 
Figure 4. Chemokine receptor expression on piperacillin-specific T-cell clones derived 663 
from blood and inflamed skin of hypersensitive patients. Piperacillin-specific T-cell 664 
clones deriving from blood and skin of hypersensitive patients were analysed for chemokine 665 
receptor expression by flow cytometry. The box plot shows the median and 25th/75th 666 
percentiles, with error bars showing the 10th/90th percentiles. 667 
 668 
Figure 5. Migration of piperacillin-specific T-cell clones derived from blood and 669 
inflamed skin of hypersensitive patients towards chemokines. Time-dependent 670 
chemotactic migration was recorded by counting using a haemocytometer between 0.5-24h. 671 
Each line shows the response of an individual clone. 672 
 673 
Figure 6. Piperacillin-specific priming of naïve T-cells from healthy volunteers. (A) 674 
Drug-specific T-cell proliferative responses were measured by [3H]thymidine uptake. The 675 
data show mean ± SD of triplicate cultures. (B) Antigen-specific T-cell responses measured 676 
by IFN-γ, IL-13, IL-17 and IL-22 ELIspot. (C) Table shows the number of piperacillin-677 
responsive T-cell clones generated from blood of healthy volunteers following priming and 678 
their CD phenotype. (D) T-cell clones were cultured with irradiated antigen presenting cells 679 
and piperacillin and proliferative responses were measured. (E) T-cell clones were cultured 680 
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with irradiated antigen presenting cells and piperacillin (2mM) and cytokine secretion was 681 
quantified.   682 
 683 
Figure 7. Profile of cytokines secreted from piperacillin-specific T-cell clones derived 684 
from healthy volunteers. T-cell clones were cultured with irradiated antigen presenting cells 685 
and piperacillin and cytokine secretion was quantified. (A) Comparison of IFN-γ and IL-13 686 
secreted by individual T-cell clones. Filled circles depict CD8+ clones. (B) Mean ± SD IL-22 687 
secretion from Th1, Th2 and Th1/2 clones. (C) Comparison of IFN-γ/IL-22 and IL-13/IL-22 688 
secretion by T-cell clones.  689 
 690 
Figure 8. Piperacillin-specific priming of naïve T-cells from healthy volunteers in the 691 
presence of an AhR agonist and antagonist. Antigen-specific T-cell responses were 692 
measured by IFN-γ, IL-13, IL-17, IL-22, granzyme B, perforin and Fas L ELIspot. (A) 693 
Piperacillin concentration-dependent secretion of cytokines/cytolytic molecules. (B) Images 694 
from one representative donor.   695 
 696 
 697 
 698 
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Figure E6 
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BR ʹ 0 
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TR ʹ 0 
BL ʹ 100 
BR ʹ 0 
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TR ʹ 0 
BL ʹ 100 
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Tube 1 
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Figure E7 
 
 
 
APC Ȃ CXCR1 
PE Ȃ CXCR3 
 
 TL Ȃ 10.0 
TR Ȃ 63.0 
BL Ȃ 7.3 
BR Ȃ 19.7 
 
 
 
APC Ȃ CXCR1 
PE Ȃ CXCR3 
 
 TL Ȃ 17.5 
TR Ȃ 58.0 
BL Ȃ 8.6 
BR Ȃ 15.9 
 
 
 
APC Ȃ CXCR1 
PE Ȃ CXCR3 
 
 TL Ȃ 18.3 
TR Ȃ 50.4 
BL Ȃ 16.2 
BR Ȃ 15.1 
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